Potential Anti-Tumor Mechanisms Of Renin Angiotensin System Inhibitors Through Inhibiting Angiogenesis And Influencing Angiotensin Ii Actions

Bei Zhao,Hong Sun,Xiao-Dan Zhang,Guang-Hui Li,Yong-Hong Zhao,Bin Wang
2018-01-01
Abstract:Recent studies have shown that renin angiotensin system (RAS) inhibitors improve the survival of patients with several types of cancer such as pancreatic cancer. However, the anti-tumor mechanisms of RAS inhibitors remain unclear. The objective of this study was to investigate the potential mechanisms of the improvement of survival by RAS inhibitors. MTT and scratch wound healing assays were conducted using pancreatic cancer cells treated with RAS inhibitors or paclitaxel as a single agent or in combination to investigate the influence of RAS inhibitors on pancreatic cancer cell proliferation and migration. Rat aortic ring assays were conducted to investigate the influence of RAS inhibitors on angiogenesis. Cell proliferation assays were conducted using human umbilical vein endothelial cells (HUVECs) treated with RAS inhibitors or angiotensin II as a single agent or in combination to investigate the influence of RAS inhibitors on angiotensin II-mediated cellular effects. Our results showed that a high concentration (100 mu M) of RAS inhibitors suppressed the proliferation of pancreatic cancer cell lines (Panc-1, Bxpc-3, and CFPAC-1) when used alone or in combination with paclitaxel, but did not influence cell migration. RAS inhibitors significantly inhibited angiogenesis in rat thoracic aorta rings. In addition, a low concentration of angiotensin II promoted the growth of HUVEC cells, whereas the high concentration suppressed cell growth. ARBs inhibited the cellular effects caused by angiotensin II in HUVEC cells, whereas ACEIs did not inhibit such effects. In conclusion, RAS inhibitors may improve survival of cancer patients by inhibition of angiogenesis and influencing angiotensin II.
What problem does this paper attempt to address?